Literature DB >> 25406312

Progranulin and a five transmembrane domain-containing receptor-like gene are the key components in receptor activator of nuclear factor κB (RANK)-dependent formation of multinucleated osteoclasts.

Jaemin Oh1, Ju-Young Kim2, Han-Soo Kim3, Justin Cheesung Oh4, Yoon-Hee Cheon5, Jongtae Park6, Kwon-Ha Yoon7, Myeung Su Lee8, Byung-Soo Youn9.   

Abstract

Homeostatic bone remodeling is vital to maintain healthy bone tissue. Although the receptor activator of nuclear factor κB ligand (RANKL)/RANK axis is considered the master regulator of osteoclastogenesis, the underlying mechanisms including cell fusion remain incompletely defined. Here, we introduce a new axis in the formation of multinucleated cells via RANK signaling: the progranulin (PGRN)/PIRO (PGRN-induced receptor-like gene during osteoclastogenesis) axis. When mouse bone marrow-derived macrophages were stimulated with PGRN in the presence of RANKL, explosive OC formation was observed. PGRN knockdown experiments suggested that endogenous PGRN is an essential component of the RANKL/RANK axis. Our efforts for identifying genes that are induced by PGRN unveiled a remarkably induced (20-fold) gene named PIRO. Substantial PGRN and PIRO expression was detected after 2 and 3 days, respectively, suggesting that their sequential induction. PIRO was predicted to be a five transmembrane domain-containing receptor-like molecule. The tissue distribution of PGRN and PIRO mRNA expression suggested that bone marrow cells are the most suitable niche. Mouse and human PIRO are part of a multigene family. Knockdown experiments suggested that PIRO is a direct target for the formation of multinucleated cells by PGRN. PGRN levels were also substantially higher in ovariectomized mice than in sham control mice. These observations suggest that PGRN and PIRO form a new regulatory axis in osteoclastogenesis that is included in RANK signaling in cell fusion and OC resorption of osteoclastogenesis, which may offer a novel therapeutic modality for osteoporosis and other bone-associated diseases.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Bone; Cell Fusion; Cytokine; Genomics; Osteoclast; Osteoporosis; Receptor

Mesh:

Substances:

Year:  2014        PMID: 25406312      PMCID: PMC4303659          DOI: 10.1074/jbc.M114.608786

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  RANK is essential for osteoclast and lymph node development.

Authors:  W C Dougall; M Glaccum; K Charrier; K Rohrbach; K Brasel; T De Smedt; E Daro; J Smith; M E Tometsko; C R Maliszewski; A Armstrong; V Shen; S Bain; D Cosman; D Anderson; P J Morrissey; J J Peschon; J Schuh
Journal:  Genes Dev       Date:  1999-09-15       Impact factor: 11.361

2.  TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.

Authors:  B R Wong; J Rho; J Arron; E Robinson; J Orlinick; M Chao; S Kalachikov; E Cayani; F S Bartlett; W N Frankel; S Y Lee; Y Choi
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

Review 4.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

Authors:  T Suda; N Takahashi; N Udagawa; E Jimi; M T Gillespie; T J Martin
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

5.  Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.

Authors:  S Morony; C Capparelli; I Sarosi; D L Lacey; C R Dunstan; P J Kostenuik
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

6.  Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis.

Authors:  Takako Koga; Masanori Inui; Kazuya Inoue; Sunhwa Kim; Ayako Suematsu; Eiji Kobayashi; Toshio Iwata; Hiroshi Ohnishi; Takashi Matozaki; Tatsuhiko Kodama; Tadatsugu Taniguchi; Hiroshi Takayanagi; Toshiyuki Takai
Journal:  Nature       Date:  2004-04-15       Impact factor: 49.962

7.  Purification of an autocrine growth factor homologous with mouse epithelin precursor from a highly tumorigenic cell line.

Authors:  J Zhou; G Gao; J W Crabb; G Serrero
Journal:  J Biol Chem       Date:  1993-05-25       Impact factor: 5.157

8.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

Review 9.  The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.

Authors:  Anna Capozzi; Stefano Lello; Alfredo Pontecorvi
Journal:  Gynecol Endocrinol       Date:  2014-03-05       Impact factor: 2.260

10.  Structure and chromosomal location of the human granulin gene.

Authors:  V Bhandari; A Bateman
Journal:  Biochem Biophys Res Commun       Date:  1992-10-15       Impact factor: 3.575

View more
  5 in total

1.  Female-Specific Role of Progranulin to Suppress Bone Formation.

Authors:  Liping Wang; Theresa Roth; Mary C Nakamura; Robert A Nissenson
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

2.  Progranulin, a moderator of estrogen/estrogen receptor α binding, regulates bone homeostasis through PERK/p-eIF2 signaling pathway.

Authors:  Yuyou Yang; Naibo Feng; Li Liang; Rong Jiang; Yiming Pan; Nana Geng; Mengtian Fan; Xiaoli Li; Fengjin Guo
Journal:  J Mol Med (Berl)       Date:  2022-07-15       Impact factor: 5.606

Review 3.  The dynamic evolution of rheumatology in Korea.

Authors:  Ho-Youn Kim; Yeong-Wook Song
Journal:  Nat Rev Rheumatol       Date:  2015-12-17       Impact factor: 20.543

4.  The Endogenous GRP78 Interactome in Human Head and Neck Cancers: A Deterministic Role of Cell Surface GRP78 in Cancer Stemness.

Authors:  Hsin-Ying Chen; Joseph Tung-Chieh Chang; Kun-Yi Chien; Yun-Shien Lee; Guo-Rung You; Ann-Joy Cheng
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

5.  DR3 and its ligands take roles in periodontium remodeling during orthodontic tooth movement.

Authors:  Chuanliang Ling; Ruolin Cai; Yiming Gong; Xiaojun Ding
Journal:  J Dent Sci       Date:  2020-03-19       Impact factor: 2.080

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.